Literature DB >> 11782597

Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men?

David M Burger, Marijke C Siebers, Patricia W H Hugen, Rob E Aarnoutse, Yechiel A Hekster, Peter P Koopmans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11782597     DOI： 10.1097/00126334-200201010-00014

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  10 in total

Review 1.  Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.

Authors:  Margalida Rotger; Chantal Csajka; Amalio Telenti
Journal:  Curr HIV/AIDS Rep       Date:  2006-09       Impact factor: 5.071

2.  Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial.

Authors:  Cynthia Firnhaber; Laura M Smeaton; Beatriz Grinsztejn; Umesh Lalloo; Sharla Faesen; Wadzanai Samaneka; Rosa Infante; Aadia Rana; Nagalingeswaran Kumarasamy; James Hakim; Thomas B Campbell
Journal:  HIV Clin Trials       Date:  2015-05-15

3.  Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women.

Authors:  Marilia Santini-Oliveira; Rita de Cássia Elias Estrela; Valdiléa Gonçalves Veloso; Vitória Berg Cattani; Carolyn Yanavich; Luciane Velasque; Thiago Silva Torres; Luana Monteiro Spindola Marins; José Henrique Pilotto; Esaú Custódio João; José Carlos Saraiva Gonçalves; Beatriz Grinsztejn
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

4.  Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.

Authors:  Obi C Umeh; Judith S Currier; Jeong-Gun Park; Yoninah Cramer; Ashwaq E Hermes; Courtney V Fletcher
Journal:  J Clin Pharmacol       Date:  2011-01-13       Impact factor: 3.126

5.  Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.

Authors:  Tim R Cressey; Saik Urien; Deborah Hirt; Guttiga Halue; Malee Techapornroong; Chureeratana Bowonwatanuwong; Prattana Leenasirimakul; Jean-Marc Treluyer; Gonzague Jourdain; Marc Lallemant
Journal:  Ther Drug Monit       Date:  2011-02       Impact factor: 3.681

6.  Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.

Authors:  Chantal Csajka; Catia Marzolini; Karin Fattinger; Laurent A Décosterd; Amalio Telenti; Jérôme Biollaz; Thierry Buclin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.

Authors:  Sarah M Robertson; Elizabeth Formentini; Raul M Alfaro; Ven Natarajan; Judith Falloon; Scott R Penzak
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

8.  Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

Authors:  Shaheena Asad; Todd Hulgan; Stephen P Raffanti; Jim Daugherty; Wayne Ray; Timothy R Sterling
Journal:  J Natl Med Assoc       Date:  2008-12       Impact factor: 1.798

9.  Sex Differences in HIV: Natural History, Pharmacokinetics, and Drug Toxicity.

Authors:  Obiamiwe C Umeh; Judith S Currier
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.663

Review 10.  Caring for women living with HIV: gaps in the evidence.

Authors:  Mona R Loutfy; Lorraine Sherr; Ulrike Sonnenberg-Schwan; Sharon L Walmsley; Margaret Johnson; Antonella d'Arminio Monforte
Journal:  J Int AIDS Soc       Date:  2013-10-01       Impact factor: 5.396
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.